Kangfang Biomedical denies selling "clinical research drugs" to patients: sales staff forged materials to scam several drugs from the company.

Recently, the entry of clinical trial anti-cancer drugs into the market has attracted industry attention, and the drug involved is Kangfang Biotech's Cetuximab. Kangfang Biotech released a statement regarding the news report on a cervical cancer patient in Chongqing using the company's drug, stating that after investigation, it was confirmed that the company never charged the patient, Li, for the clinical research drug, and the company's sales staff also did not charge Li. There was no situation where the patient "paid for the clinical research drug." The statement mentioned that the company's Chongqing sales staff obtained some drugs from the company by forging research project approval documents and hospital ethics approvals, claiming it was for the post-launch clinical research by the investigator, and provided the drugs to Li for free. According to the sales staff, they provided the drug to Li for free multiple times because they considered her limited ability to pay and the good effectiveness of Cetuximab injection. Kangfang Biotech emphasized that the drugs obtained for free by Li were produced strictly in accordance with national GMP standards, and the same rigorous drug quality management requirements were applied as for the company's commercial products.